PCBL Chemical has announced that its Q1FY27 earnings conference call will be held on July 29, 2026, at 17:00 IST. The event is designed to provide investors and analysts with a detailed overview of the company’s financial and operational performance for the first quarter of fiscal year 2027. This scheduled disclosure follows the company's recent financial reporting cycle, offering stakeholders a direct channel to engage with senior leadership regarding quarterly outcomes.

Earnings Call Details

The conference call will be conducted pursuant to Regulations 30 and 46(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The session aims to clarify performance metrics and strategic updates without sharing any unpublished price-sensitive information (UPSI) prior to the formal discussion.

Management Participation

Senior executives from PCBL Chemical Limited will lead the discussion, providing insights into the company's recent results. The key participants include:

• Nilesh Koul, Managing Director
• Rohit Narang, CEO Aquapharm Chemical
• Raj Gupta, CFO
• Pankaj Kedia, Executive Director - IR

The call is being coordinated by ICICI Securities, which has issued invitations to investors and analysts. Participants can register via the Diamond Pass link provided in the official notice. For logistical support, ICICI Securities has designated contact points including Jaideep Goswami, Head of Equities, and other team members such as Sanjesh Jain, Mohit Mishra, Rushad Kapadia, Seema Sehgal, and Minali Ginwala.

Regulatory Compliance

PCBL Chemical Limited submitted the intimation to the National Stock Exchange of India Ltd and BSE Ltd on July 24, 2026. The disclosure was signed by Kaushik Mukherjee, Company Secretary and Chief Legal Officer, affirming compliance with SEBI Listing Regulations. The company noted that the schedule is subject to change due to exigencies, if any, though no alterations have been reported as of the filing date.

What the Numbers Show

While specific financial figures for Q1FY27 have not been disclosed in this notice, the scheduling of the call indicates the completion of the quarter's audit and finalization of accounts. Investors should monitor the call for details on revenue growth, margin trends, and operational efficiencies in the chemical and pharmaceutical segments, particularly given the active participation of the CEO of Aquapharm Chemical, suggesting potential segment-specific updates.

R K Agarwal ceased to be an Independent Director of pcbl chemical on July 25, 2026, following the completion of his term. The exit marks the end of his contributions to the Board, including his roles in key oversight committees. Consequently, he also stepped down as a member of the Audit Committee and the Sustainability and Risk Management Committee. The Board recorded its appreciation for his service during his tenure. This change ensures compliance with regulatory norms regarding director tenure limits while maintaining committee continuity through immediate reconstitution.

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The cessation took effect at the close of business hours on July 25, 2026. The company notified both the National Stock Exchange of India Ltd and BSE Ltd regarding the change in directorship composition.

To maintain the integrity of its oversight structures, the Board approved the induction of Umang Kanoria (DIN: 00081108) as a Member of the Audit Committee, effective July 25, 2026. This appointment followed a recommendation from the Nomination and Remuneration Committee and was formalized via a Circular Resolution passed by the Board of Directors on the same day. Kanoria’s entry ensures that the Audit Committee remains fully constituted and compliant with listing requirements.

The reconstituted Audit Committee now comprises three independent directors. T C Suseel Kumar serves as Chairman, supported by Dr. S Ravi and Umang Kanoria as members. This structure preserves the independence and expertise required for effective financial oversight and risk management within the organization.

Key Changes in Board Composition

Governance Implications

The transition highlights the company’s adherence to statutory timelines for director rotation and committee reconstitution. By appointing Kanoria simultaneously with Agarwal’s exit, the Board avoided any gap in Audit Committee membership, which is critical for ongoing financial reporting and compliance activities. The retention of T C Suseel Kumar as Chairman provides stability during this leadership transition.